



ASX Announcement

17 October 2019

September 2019 Quarterly Report

Invex Therapeutics Ltd (Invex, ASX: IXC, or the Company) is pleased to provide a corporate and operational update to accompany its Appendix 4C for the quarter ended September 2019.

Operational Update

Clinical Research Activities

The Company is currently in the process of reformulating Exenatide to optimise the delivery of the drug for patients with diseases involving raised intracranial pressure. In the third quarter, work progressed as planned and a number of potential formulations were identified which will be evaluated in-vivo in the fourth quarter of this year.

Finally, the Phase II randomised double blinded study of Exenatide in Idiopathic Intracranial Hypertension progressed ahead of schedule (IIH - a severe condition which can lead to disabling headaches and permanent vision loss). The last patient was dosed on 15 October 2019 and top-line data should be available in the first half of 2020.

Intellectual Property Portfolio

The Company is actively pursuing patent applications at both the European and the US patent offices. On 7 October 2019 the Company announced that patent number 2017-512008 had been granted by the Japanese Patent Office. The patent relates to the treatment of undesirable increased intracranial pressure. Elevated intracranial pressure is observed in subjects with IIH as well as a broader group of diseases including, but not limited to, secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, meningitis, brain trauma, brain injury and venous sinus thrombosis.

Corporate

Annual General Meeting

The Company's Annual General Meeting (AGM) will be held at Level 2, 16 O'Connell St, Sydney on Thursday 21 November 2019 at 10.00am (EDST). Dr Loveridge and Professor Sinclair will attend the AGM and meet shareholders and potential investors during the week prior to the AGM.

The Company closed the quarter with a cash position of \$11.116 million.



Outlook

Invex has laid strong foundations and plans to rapidly progress the development and commercialisation of treatments for IIH and other specific neurological conditions derived from raised intracranial pressure. The Company has already made significant progress in its development activities and is anticipating data from its Phase II clinical study in the first half of 2020.

ENDS

For more information, please contact:

Company

David McAuliffe

Non Executive Director

dmcauliffe@invextherapeutics.com

+61 408 994 313

Media

Margie Livingston

Ignite Communications

margie@ignitecommunications.com.au

+61 438 661 131

Investors

Nicole Fernandes

NFIC Services

nicole@nfciservices.com.au

+61 407 101 701

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. www.invextherapeutics.com

Exenatide

- Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which received approval in the US and Europe for the treatment of type 2 diabetes in 2005 and 2006 respectively.
- Professor Sinclair's research showed that GLP-1 receptors are expressed in the choroid plexus in the brain and that Exenatide can bind to these receptors and reduce secretion of cerebrospinal fluid.
- Current Exenatide dosage forms are not optimised for IIH.

Idiopathic Intracranial Hypertension (IIH)

- IIH features severely raised intracranial pressure which causes disabling daily headaches and compresses the optic nerve, causing permanent vision loss in 25% of those affected.
- The usual age of onset is 20-30 years, and it is most common in women who are obese.
- IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Invex Therapeutics Ltd

ABN

29 632 145 334

Quarter ended ("current quarter")

30 September 2019

Consolidated statement of cash flows	Current quarter \$A'000	30 Sept \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(59)	(59)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	-	-
(f) administration and corporate costs	(142)	(142)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	48	48
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other – D&O insurance	(53)	(53)
1.9 Net cash from / (used in) operating activities	(206)	(206)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-

Consolidated statement of cash flows	Current quarter \$A'000	30 Sept \$A'000
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	-	-

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	(848)	(848)
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	(848)	(848)

Consolidated statement of cash flows		Current quarter \$A'000	30 Sept \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	12,170	12,170
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(206)	(206)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(848)	(848)
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of quarter	11,116	11,116

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,116	12,170
5.2	Call deposits	10,000	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	11,116	12,170

6. Payments to directors of the entity and their associates	Current quarter \$A'000
6.1 Aggregate amount of payments to these parties included in item 1.2	74
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

\$17,500 was paid to Prof. Alexander Sinclair for Executive director services.
 \$8,750 was paid to David McAuliffe for Non-executive Director fees.
 \$8,750 was paid to Warambi Sarl, a company controlled by Dr Jason Loveridge for Non-executive director fees.
 \$8,750 was paid to Warambi Ltd, a company controlled by Dr Jason Loveridge for R&D consultancy services.
 \$30,000 was paid to Concept Biotech Pty Ltd, a company which David McAuliffe and Narelle Warren are directors and shareholders for the provision of accounting and company secretarial services.
 \$25,000 was paid to Concept Biotech Pty Ltd, a company which David McAuliffe and Narelle Warren are directors and shareholders for the provision of due diligence and project management services in relation to the IPO. This amount is included at item 3.4.

7. Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

--	--

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	(594)
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	-
9.6 Administration and corporate costs	(123)
9.7 Other	-
9.8 Total estimated cash outflows	(717)

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here:Date: 17 October 2019.....
(Director/Company secretary)

Print name: Narelle Warren

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.